top of page


Dr. Sindhu Johnson graduated from medical school at Memorial University of Newfoundland, Canada followed by residencies in Internal Medicine and Rheumatology at the University of Toronto. She completed a PhD in Clinical Epidemiology through the Institute of Health Policy, Management and Evaluation.


Dr. Johnson is a Rheumatologist and Clinician-Scientist at the University Health Network and Sinai Health Systems. She is Directorship of the Toronto Scleroderma Program and an Associate Professor of Medicine at the University of Toronto. She is also the Associate Director of the Clinical Epidemiology and Health Care Research Program at the University of Toronto.


Her research focuses on observational studies and clinical trials to better understand scleroderma, how it impacts peoples’ lives, develop better treatments and discover a cure. She has published on aspects of scleroderma including the epidemiology of overlap syndromes (scleroderma-SLE (JRheum 2019)), environmental risk factors (Rheum Dis Clin NA 2022), comorbidities (blood clots (JRheum 2018), nerve damage (JRheum 2021)), treatments (Botox (Best Practice & Research 2021)), employment outcomes (Best Practice & Research 2021), and ethnic variations in disease and outcomes (JRheum 2019). Of note, she was an investigator for studies that led to the first two US Food and Drug Administration approved medicines for scleroderma (nintedinib, tocilizumab).

bottom of page